The invention relates to pentafluorosulfanyl benzoylguanidines of formula (I), in which R1 to R4 are defined as cited in the claims. Said substances are suitable for use as anti-arrhythmic medicaments comprising cardio-protective components for the prophylaxis and treatment of infarcts, in addition to the treatment of angina pectoris. They also preventatively inhibit the pathophysiological events that occur during ischaemically induced traumas, in particular during the triggering of ischaemically induced cardiac arrhythmia.